Image for Cardiovascular Pharmacology Concepts, Richard E Klabunde PhD

Cardiovascular Pharmacology Concepts

Richard E. Klabunde, PhD

Clinical Disorders:

Therapeutic Classes:

Mechanism Classes:

Also Visit

Cardiovascular Physiology Concepts 3e textbook cover

Click here for information on Cardiovascular Physiology Concepts, 3rd edition, a textbook published by Wolters Kluwer (2021)


Cardiovascular Physiology Concepts textbook cover

Click here for information on Normal and Abnormal Blood Pressure, a textbook published by Richard E. Klabunde (2013)


Angiotensin Receptor Blockers (ARBs)

General Pharmacology

These drugs have very similar effects to angiotensin converting enzyme (ACE) inhibitors and are used for the same indications (hypertension, heart failure, post-myocardial infarction). Their mechanism of action, however, differs from ACE inhibitors, which inhibit the formation of angiotensin II. ARBs are receptor antagonists that block type 1 angiotensin II (AT1) receptors on blood vessels and other tissues, such as the heart. These receptors are coupled to the Gq-protein and IP3 signal transduction pathway that stimulates vascular smooth muscle contraction. Because ARBs do not inhibit ACE, they do not cause an increase in bradykinin, which contributes to the vasodilation produced by ACE inhibitors and also some of the side effects of ACE inhibitors (cough and angioedema).

Similar to ACE inhibitors, ARBs have the following actions:

Therapeutic Uses

ARBs are used in the treatment of hypertension and heart failure, similarly to ACE inhibitors (see ACE inhibitors for details). Valsartan is the only ARB approved for post-myocardial infarction.

Specific Drugs

ARBs include the following drugs: 

Note that each of the ARBs named above ends with "sartan."

Side Effects and Contraindications

As a drug class, ARBs have a relatively low incidence of side effects and are well-tolerated. Because they do not increase bradykinin levels like ACE inhibitors, the incidence of dry cough and angioedema is lower than with ACE inhibitors. Using ARBs may lead to hyperkalemia, as occurs with ACE inhibitors, especially in patients taking a potassium-sparing diuretic. ARBs are contraindicated in pregnancy. Patients with bilateral renal artery stenosis may experience renal failure if ARBs are administered. The reason is that the elevated circulating and intrarenal angiotensin II in this condition constricts the efferent arteriole more than the afferent arteriole within the kidney, which helps to maintain glomerular capillary pressure and filtration. Removing this constriction by blocking angiotensin II receptors on the efferent arteriole can cause an abrupt fall in glomerular filtration rate. This is not usually a problem with unilateral renal artery stenosis because the unaffected kidney can maintain sufficient filtration after AT1 receptors are blocked; however, with bilateral renal artery stenosis, it is especially important to ensure that renal function is not compromised.

Revised 10/18/2022

DISCLAIMER: These materials are for educational purposes only, and are not a source of medical decision-making advice.